Results 121 to 130 of about 40,773 (330)

New prospects for PCSK9 inhibition? [PDF]

open access: yesEuropean Heart Journal, 2018
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018.
U. Landmesser   +22 more
openaire   +5 more sources

Depletion of Hepatic SREBP2 Protects Against Hypercholesterolemia and Atherosclerosis through the ANGPTL3‐LPL Axis

open access: yesAdvanced Science, EarlyView.
This study reveals a novel crosstalk between hepatic SREBP2‐mediated cholesterol biosynthesis pathway and peripheral lipoprotein lipase‐mediated lipolysis pathway in the regulation of systemic lipid metabolism. Notably, the lipid‐lowering effects of SREBP2 inhibition are independent of a functional LDL receptor, highlighting the potential of acute ...
Yifan Wang   +13 more
wiley   +1 more source

PCSK9 Inhibition

open access: yesJournal of the American College of Cardiology, 2012
Statins have been approved for the treatment of dyslipidemia for 25 years. This class has demonstrated substantial and consistent reduction of cardiovascular events with an acceptable safety profile. Despite the widespread use of statins, patients continue to experience residual risk. To date,
openaire   +3 more sources

Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD‐1 Blockade in MSS Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
xxxx. Abstract Nutrient metabolisms are vitally interrelated to cancer progression and immunotherapy. However, the mechanisms by which nutrient metabolisms interact to remodel immune surveillance within the tumor microenvironment remain largely unexplored.
Qi‐Long Wang   +16 more
wiley   +1 more source

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

open access: yesJournal of Lipid Research, 2014
Secreted PCSK9 binds to cell surface LDL receptor (LDLR) and directs the receptor for lysosomal degradation. PCSK9 is potent at inducing LDLR degradation in cultured liver-derived cells, but it is considerably less active in immortalized fibroblasts.
My-Anh Nguyen   +2 more
doaj  

Studies on PCSK9 in the regulation of cholesterol metabolism [PDF]

open access: yes, 2011
Elevated levels of plasma cholesterol, mainly in low density lipoproteins (LDL), are a major risk factor for coronary heart disease. The level of plasma LDL cholesterol (LDL-C) is largely dependent on the number of hepatic LDL receptors (LDLRs ...
Persson, Lena
core   +1 more source

Gene Therapy Targeting PCSK9

open access: yesMetabolites, 2022
The last decades of research in cardiovascular prevention have been characterized by successful bench-to-bedside developments for the treatment of low-density lipoprotein (LDL) hypercholesterolemia.
J. Katzmann, A. Cupido, U. Laufs
semanticscholar   +1 more source

PCSK9 monoclonal antibodies: An overview

open access: yesHeart Views, 2020
PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma level resulting in a better LDL-C goal attainment.
Bassant Orabi   +2 more
openaire   +4 more sources

The contribution of extracellular RNA and its derived biomaterials in disease management

open access: yesBMEMat, EarlyView.
The implications of exRNA's biological function and the structural uniqueness of RNA help establish a close connection between RNA, material, and modern medicine. Abstract The RNA found in the circular system is known as extracellular RNA (exRNA). This kind of RNA has been found to play a biological role similar to that of a messenger. They can be used
Yu Wei   +8 more
wiley   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis

open access: yesLipids in Health and Disease, 2021
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cholesterol metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients with liver cirrhosis.
Susanne Feder   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy